Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it failed to meet its primary endpoint in its Phase 2 trial of CH-4051 in patients with rheumatoid arthritis (RA). As a result it plans to discontinue development of CH-4051.
Alkermes plc (NASDAQ: ALKS) said that it did not meet its “pre-specified criteria for advancing into Phase 3 clinical trials” following data from its Phase 2b trial of ALKS 37 in the treatment of opioid-induced constipation. The company said it has no further plans to advance ALKS 37.
Omeros Corporation (NASDAQ: OMER) today maintained previous guidance that it plans to announce data from its second Phase 3 OMS302 trial, in patients undergoing intraocular lens replacement (ILR) surgery, in 2H 2012 and, assuming positive results, to file both an NDA and MAA in the first part of 2013.